Interview with Jenny Winter, Managing Director, AstraZeneca Hungary
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Address: 1113 Budapest, Bocskai út 134-146. Hungary,Hungary
Tel: +36 1 883 6500
Web: http://www.astrazeneca.hu/
We are active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.
We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia).
We invest over $4 billion in R&D each year. Around 15,7001 people work in our R&D organisation and we have 14 major R&D centres in eight countries, including Sweden, the US and the UK.
We have 9,300 employees at 23 supply and manufacturing sites in 16 countries.
In 2010, our worldwide sales totalled over $33 billion (including 10 medicines with sales of over $1 billion each).
Alongside our commitment to competitiveness and performance, we continue to be led by our core values to deliver business success responsibly. We are positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indexes.
We focus our skills and resources on six important areas of healthcare, which include some of the world’s most serious illnesses:
– Cardiovascular
– Gastrointestinal
– Infection
– Neuroscience
– Oncology
– Respiratory
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Dr Miklós Kellermayer elaborates on his priorities to implement a more practical, experience-focused curriculum as the recently appointed Dean of the Faculty of Medicine of Semmelweis University. Dr Kellermayer goes…
Veronika Ferencz, general manager of Exeltis Hungary, gives an update on the recent activies and achievement of the affiliate since her last PharmaBoardroom interview in 2016. Furthermore, Ferencz goes on…
István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the…
Prof. Éva Szökő, president of the Hungarian Society for Pharmaceutical Sciences (MGYT), shares her insights on the activities of the society, its collaboration with institutions and industry players in the…
Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic…
Dr Mátyás Szentiványi, Director General of the National Institute of Pharmacy and Nutrition (OGYEI), introduces the administrative authority and specifies his strategy to be an increasingly collaborative and communicative body…
Dr. Péter Ofner, Former Director of the Gottsegen Hungarian Insititute of Cardiology, shares his insights on the cardiological capabilities of the institute, the epidemiological profile of the country, the collaborations…
Dr. György Blaskó, former President and Chairman of the Hungarian European Clinical Research Infrastructure Network, explains the role of the research network, the impact it has on the Hungarian clinical…
Dr. György Bagdy, professor and former vice rector at Semmelweis University, shares his insights on the longstanding history of pharmacology in Hungary, the key strengths of the country in the…
Hungarian national champion Egis and French Big Pharma Sanofi have both made recent big-ticket investments in new facilities in Hungary. Egis’ new manufacturing plant in Körmend and Sanofi’s new shared…
Dr. József Mandl, President of the Medical Research Council (ETT), discusses the role of the council, the research environment in Hungary, its relationship with the European Clinical Research Infrastructure Network…
Júlia Lipovecz, director of Swisscham Hungary, shares insights into the association and its activities to promote Swiss foreign investment in Hungary, the importance of local collaboration, and how its members…
See our Cookie Privacy Policy Here